Advances on Nanomedicines for Diagnosis and Theranostics of Hepatic Fibrosis

Abstract

Hepatic fibrosis is induced by chronic hepatic injuries before it turns into hepatic cirrhosis/carcinoma. It is characterized by the formation of collagen and other extracellular matrices around damaged hepatic tissues; consequently, the normal architecture of liver would be disrupted and its function impaired. Diagnosis of hepatic fibrosis, especially at the early stage, is crucial because most fibrotic changes are reversible during the hepatic fibrosis stage. However, early and more accurate diagnosis of hepatic fibrosis still remains a great challenge. With their promising structural adjustability and targeting ability, nanomedicines have recently been introduced to improve diagnosis of hepatic fibrosis. By targeting fibrogenic cells, receptors, and extracellular matrix components, these nanomedicines can achieve detection of hepatic tissues with high sensitivity and specificity at the early stage. The use of nanomedicines can also enable theranostics of this chronic hepatic disease. This review aims to present an overview of recent advances of nanomedicines in diagnosis and theranostics of hepatic fibrosis.

Nanomedicines for high‑intensity focused ultrasound cancer treatment and theranostics (Review)

“…Although progress has been made in this field, challenges remain regarding these HIFU-appliable nanomedicines before they can be used clinically. Although most of these nanomedicines have been reported to exhibit low toxicity in vivo , a degree of hepatotoxicity is observed, often as hepatic fibrosis, particularly in patients with hepatoma ( 131 , 132 ). Thus, it is important to assess and minimise the toxicity and side effects of these nanomedicines.…”